PSS World Medical's Physician Division to Distribute the Sunlight OmnisenseTM 7000S Bone Sonometer
Somerset, NJ, USA (October 25, 2001) Sunlight Medical, Inc.,
a leading provider of hi-tech medical solutions,
has signed an agreement with Physician Sales and Service (PSS),
a division of PSS World Medical (NASDAQ/NM: PSSI) to distribute
Sunlight Omnisense™ 7000S, the world's only multi-site bone sonometer, in all 50 states.
Omnisense, successfully marketed in the United States since its entry into the market in January 2001,
is a quantitative-ultrasound device developed for point-of-care screening, diagnosing and monitoring of osteoporosis.
Markus Maritz, president of Sunlight Medical, Inc.,
is pleased about the agreement and the new marketing opportunities
it offers for Omnisense. "The addition of PSS to our distribution network
is a major step forward," he explains. "We expect that working together with PSS
will help bring our device to more primary care physicians and broaden the scope
of timely diagnosis of osteoporosis in the United States."
The management of PSS, a leading distributor of medical supplies to the physician market
in the United States, is also excited about the possibilities opened up by the new agreement.
"Adding Sunlight OmnisenseTM 7000S to our product portfolio fits well with our strategy to offer
the latest technology solutions to our customers," explained Doug Harper, president of PSS.
"The growing awareness of osteoporosis, combined with the available treatments for the disease,
will continue to raise customer demand for Omnisense." PSS World Medical, Inc. is a specialty marketer
and distributor of medical products to physicians, long-term care providers and imaging consumers through
its three business units to customers in all 50 states. Since its inception in 1983, PSS has become a
leader in all three market segments that it serves with a focused market approach to customer service,
a consultative sales force, strategic acquisitions, strong arrangements with product manufacturers and
a unique culture of performance.
Sunlight Medical, Inc. is the North American subsidiary of Sunlight Medical,
an international company with offices in Germany, Israel, China, and the United States.
Sunlight develops, manufactures, and markets cutting-edge medical devices designed for
point-of-care physicians. Its flagship product, Sunlight OmnisenseTM 7000S,
is sold in over 30 countries and has gained wide recognition in the international medical community.
For more information on Sunlight Medical, Inc. or the Sunlight OmnisenseTM 7000S bone sonometer,
contact David Helowicz, National Sales Manager, at (800) 750 6011, ext. 318 or visit www.sunlightmedical.com.
For more information on PSS World Medical, Inc. contact Richard Hansen, Director, Investor Relations at (904) 332-3287 or visit www.pssd.com.
All statements in this release that are not historical facts,
including, but not limited to, statements regarding anticipated growth in revenue,
gross margins and earnings, statements under the heading "Goals," statements
regarding the Company's current business strategy, the Company's projected sources
and uses of cash, and the Company's plans for future development and operations,
are based upon current expectations. These statements are forward looking in nature
and involve a number of risks and uncertainties. Actual results may differ materially.
Among the factors that cause results to differ materially are the following:
the availability of sufficient capital to finance the Company's business plans
and terms satisfactory to the Company; competitive factors; the ability of the Company
to adequately defend or reach a settlement of outstanding litigations and investigations
involving the Company or its management; changes in labor, equipment and capital costs;
changes in regulations affecting the Company's business; future acquisitions or
strategic partnerships; general business and economic conditions; and other factors
described from time to time in the Company's report filed with the Securities and Exchange
Commission. Many of these factors are outside the control of the Company. The Company
wishes to caution readers not to place undue reliance on any such forward looking statements,
which statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and,
as such, speak only as of the date made.